Most Read Articles
Roshini Claire Anthony, 23 Jul 2020

Dapagliflozin reduced the incidence of new-onset type 2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF), according to a prespecified exploratory analysis of the DAPA-HF* trial.

Co-formulation once-daily Insulin degludec/insulin aspart: One insulin for both initiation and intensification

23 Jul 2020
Diabetes mellitus (DM) is a highly prevalent disease,1 for which therapy has continually evolved over the years. Currently, there are various non-insulin options available for managing diabetes2; however, insulin remains one of the cornerstones of therapy. The development of new insulin options offers many advantages in achieving glycemic control but minimizing the risks of therapy, especially hypoglycemia. In a Novo Nordisk-sponsored lunch symposium entitled “Leading the Path in Diabetes Care: Insulin and Beyond” during the 20th Asian Federation of Endocrine Societies (AFES) Congress on 21 November 2019 at the Philippine International Convention Center, Dr Bien Matawaran discussed the advantages and disadvantages of various insulin options, with emphasis on the studies regarding the unique co-formulation once-daily 70% insulin degludec/30% insulin aspart (IDegAsp).

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 23 Jul 2020

Dapagliflozin reduced the incidence of new-onset type 2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF), according to a prespecified exploratory analysis of the DAPA-HF* trial.